Prevalence  ||| S:0 E:11 ||| NNP
and  ||| S:11 E:15 ||| CC
risk  ||| S:15 E:20 ||| NN
factors  ||| S:20 E:28 ||| NNS
for  ||| S:28 E:32 ||| IN
self-reported  ||| S:32 E:46 ||| FW
chronic  ||| S:46 E:54 ||| FW
disease  ||| S:54 E:62 ||| FW
amongst  ||| S:62 E:70 ||| FW
Inuvialuit  ||| S:70 E:81 ||| FW
populations  ||| S:81 E:93 ||| FW
Chronic  ||| S:93 E:101 ||| FW
disease  ||| S:101 E:109 ||| FW
prevalence  ||| S:109 E:120 ||| FW
amongst  ||| S:120 E:128 ||| FW
Canadian  ||| S:128 E:137 ||| NNP
Arctic  ||| S:137 E:144 ||| NNP
populations  ||| S:144 E:156 ||| NN
is  ||| S:156 E:159 ||| VBZ
increasing ||| S:159 E:169 ||| VBG
,  ||| S:169 E:171 ||| ,
but  ||| S:171 E:175 ||| CC
the  ||| S:175 E:179 ||| DT
literature  ||| S:179 E:190 ||| NN
amongst  ||| S:190 E:198 ||| IN
Inuvialuit  ||| S:198 E:209 ||| NNP
is  ||| S:209 E:212 ||| VBZ
limited ||| S:212 E:219 ||| VBN
.  ||| S:219 E:221 ||| .
The  ||| S:221 E:225 ||| DT
present  ||| S:225 E:233 ||| JJ
study  ||| S:233 E:239 ||| NN
aimed  ||| S:239 E:245 ||| VBN
to  ||| S:245 E:248 ||| TO
provide  ||| S:248 E:256 ||| VB
baseline  ||| S:256 E:265 ||| JJ
data  ||| S:265 E:270 ||| NNS
that  ||| S:270 E:275 ||| WDT
could  ||| S:275 E:281 ||| MD
be  ||| S:281 E:284 ||| VB
used  ||| S:284 E:289 ||| VBN
to  ||| S:289 E:292 ||| TO
monitor  ||| S:292 E:300 ||| VB
changes  ||| S:300 E:308 ||| NNS
in  ||| S:308 E:311 ||| IN
chronic  ||| S:311 E:319 ||| JJ
disease  ||| S:319 E:327 ||| NN
risk  ||| S:327 E:332 ||| NN
factors  ||| S:332 E:340 ||| NNS
and  ||| S:340 E:344 ||| CC
long-term  ||| S:344 E:354 ||| JJ
health  ||| S:354 E:361 ||| NN
in  ||| S:361 E:364 ||| IN
the  ||| S:364 E:368 ||| DT
Arctic  ||| S:368 E:375 ||| NNP
by  ||| S:375 E:378 ||| IN
determining  ||| S:378 E:390 ||| VBG
prevalence  ||| S:390 E:401 ||| NNS
and  ||| S:401 E:405 ||| CC
risk  ||| S:405 E:410 ||| NN
factors  ||| S:410 E:418 ||| NNS
of  ||| S:418 E:421 ||| IN
self-reported  ||| S:421 E:435 ||| JJ
chronic  ||| S:435 E:443 ||| JJ
disease  ||| S:443 E:451 ||| NN
amongst  ||| S:451 E:459 ||| IN
adult  ||| S:459 E:465 ||| NN
Inuvialuit  ||| S:465 E:476 ||| NNS
in  ||| S:476 E:479 ||| IN
remote  ||| S:479 E:486 ||| JJ
communities ||| S:486 E:497 ||| NNS
.  ||| S:497 E:499 ||| .
Self-reported  ||| S:499 E:513 ||| JJ
demographics  ||| S:513 E:526 ||| NNS
and  ||| S:526 E:530 ||| CC
history  ||| S:530 E:538 ||| NN
of  ||| S:538 E:541 ||| IN
chronic  ||| S:541 E:549 ||| JJ
disease  ||| S:549 E:557 ||| NN
( ||| S:557 E:558 ||| -LRB-
hypertension ||| S:558 E:570 ||| NN
,  ||| S:570 E:572 ||| ,
heart  ||| S:572 E:578 ||| NN
disease ||| S:578 E:585 ||| NN
,  ||| S:585 E:587 ||| ,
diabetes  ||| S:587 E:596 ||| NN
and  ||| S:596 E:600 ||| CC
cancer ||| S:600 E:606 ||| NN
)  ||| S:606 E:608 ||| -RRB-
were  ||| S:608 E:613 ||| VBD
collected  ||| S:613 E:623 ||| VBN
in  ||| S:623 E:626 ||| IN
three  ||| S:626 E:632 ||| CD
communities  ||| S:632 E:644 ||| NNS
between  ||| S:644 E:652 ||| IN
July  ||| S:652 E:657 ||| NNP
2007  ||| S:657 E:662 ||| CD
and  ||| S:662 E:666 ||| CC
July  ||| S:666 E:671 ||| NNP
2008  ||| S:671 E:676 ||| CD
in  ||| S:676 E:679 ||| IN
the  ||| S:679 E:683 ||| DT
Northwest  ||| S:683 E:693 ||| NNP
Territories ||| S:693 E:704 ||| NNPS
.  ||| S:704 E:706 ||| .
Food  ||| S:706 E:711 ||| NNP
frequency  ||| S:711 E:721 ||| FW
questionnaires  ||| S:721 E:736 ||| FW
recorded  ||| S:736 E:745 ||| FW
dietary  ||| S:745 E:753 ||| FW
intake ||| S:753 E:759 ||| FW
,  ||| S:759 E:761 ||| ,
International  ||| S:761 E:775 ||| NNP
Physical  ||| S:775 E:784 ||| NNP
Activity  ||| S:784 E:793 ||| NNP
Questionnaires  ||| S:793 E:808 ||| NNP
recorded  ||| S:808 E:817 ||| VBD
physical  ||| S:817 E:826 ||| JJ
activity  ||| S:826 E:835 ||| NN
and  ||| S:835 E:839 ||| CC
anthropometric  ||| S:839 E:854 ||| JJ
measures  ||| S:854 E:863 ||| NNS
of  ||| S:863 E:866 ||| IN
height  ||| S:866 E:873 ||| NN
and  ||| S:873 E:877 ||| CC
weight  ||| S:877 E:884 ||| NN
were  ||| S:884 E:889 ||| VBD
obtained ||| S:889 E:897 ||| VBN
.  ||| S:897 E:899 ||| .
Response  ||| S:899 E:908 ||| NN
rates  ||| S:908 E:914 ||| NNS
ranged  ||| S:914 E:921 ||| VBD
from  ||| S:921 E:926 ||| IN
65-85 ||| S:926 E:931 ||| CD
% ||| S:931 E:932 ||| NN
.  ||| S:932 E:934 ||| .
More  ||| S:934 E:939 ||| RBR
than  ||| S:939 E:944 ||| IN
20 ||| S:944 E:946 ||| CD
%  ||| S:946 E:948 ||| NN
of  ||| S:948 E:951 ||| IN
the  ||| S:951 E:955 ||| DT
228  ||| S:955 E:959 ||| CD
participants  ||| S:959 E:972 ||| NNS
aged  ||| S:972 E:977 ||| VBN
19-84  ||| S:977 E:983 ||| CD
years  ||| S:983 E:989 ||| NNS
reported  ||| S:989 E:998 ||| VBD
having  ||| S:998 E:1005 ||| VBG
a  ||| S:1005 E:1007 ||| DT
chronic  ||| S:1007 E:1015 ||| JJ
disease ||| S:1015 E:1022 ||| NN
.  ||| S:1022 E:1024 ||| .
Age-adjusted  ||| S:1024 E:1037 ||| JJ
prevalence  ||| S:1037 E:1048 ||| NN
was  ||| S:1048 E:1052 ||| VBD
28 ||| S:1052 E:1054 ||| CD
,  ||| S:1054 E:1056 ||| ,
9 ||| S:1056 E:1057 ||| CD
,  ||| S:1057 E:1059 ||| ,
9  ||| S:1059 E:1061 ||| CD
and  ||| S:1061 E:1065 ||| CC
6  ||| S:1065 E:1067 ||| CD
per  ||| S:1067 E:1071 ||| IN
100  ||| S:1071 E:1075 ||| CD
for  ||| S:1075 E:1079 ||| IN
hypertension ||| S:1079 E:1091 ||| NN
,  ||| S:1091 E:1093 ||| ,
heart  ||| S:1093 E:1099 ||| NN
disease ||| S:1099 E:1106 ||| NN
,  ||| S:1106 E:1108 ||| ,
diabetes  ||| S:1108 E:1117 ||| NN
and  ||| S:1117 E:1121 ||| CC
cancer ||| S:1121 E:1127 ||| NN
,  ||| S:1127 E:1129 ||| ,
respectively ||| S:1129 E:1141 ||| RB
.  ||| S:1141 E:1143 ||| .
Compared  ||| S:1143 E:1152 ||| VBN
with  ||| S:1152 E:1157 ||| IN
non-cases ||| S:1157 E:1166 ||| NNP
,  ||| S:1166 E:1168 ||| ,
participants  ||| S:1168 E:1181 ||| NNS
reporting  ||| S:1181 E:1191 ||| VBG
hypertension  ||| S:1191 E:1204 ||| NN
were  ||| S:1204 E:1209 ||| VBD
more  ||| S:1209 E:1214 ||| RBR
likely  ||| S:1214 E:1221 ||| JJ
to  ||| S:1221 E:1224 ||| TO
have  ||| S:1224 E:1229 ||| VB
a  ||| S:1229 E:1231 ||| DT
higher  ||| S:1231 E:1238 ||| JJR
body  ||| S:1238 E:1243 ||| NN
mass  ||| S:1243 E:1248 ||| NN
index  ||| S:1248 E:1254 ||| NN
and  ||| S:1254 E:1258 ||| CC
a  ||| S:1258 E:1260 ||| DT
lower  ||| S:1260 E:1266 ||| JJR
level  ||| S:1266 E:1272 ||| NN
of  ||| S:1272 E:1275 ||| IN
education ||| S:1275 E:1284 ||| NN
.  ||| S:1284 E:1286 ||| .
Hypertension  ||| S:1286 E:1299 ||| NNP
was  ||| S:1299 E:1303 ||| VBD
more  ||| S:1303 E:1308 ||| RBR
common  ||| S:1308 E:1315 ||| JJ
amongst  ||| S:1315 E:1323 ||| JJ
participants  ||| S:1323 E:1336 ||| NNS
reporting  ||| S:1336 E:1346 ||| VBG
heart  ||| S:1346 E:1352 ||| NN
disease  ||| S:1352 E:1360 ||| NN
and  ||| S:1360 E:1364 ||| CC
diabetes  ||| S:1364 E:1373 ||| NN
than  ||| S:1373 E:1378 ||| IN
Inuvialuit  ||| S:1378 E:1389 ||| NNP
not  ||| S:1389 E:1393 ||| RB
reporting  ||| S:1393 E:1403 ||| VBG
these  ||| S:1403 E:1409 ||| DT
morbidities ||| S:1409 E:1420 ||| NN
.  ||| S:1420 E:1422 ||| .
Inuvialuit  ||| S:1422 E:1433 ||| JJ
participants  ||| S:1433 E:1446 ||| NNS
in  ||| S:1446 E:1449 ||| IN
this  ||| S:1449 E:1454 ||| DT
study  ||| S:1454 E:1460 ||| NN
were  ||| S:1460 E:1465 ||| VBD
most  ||| S:1465 E:1470 ||| RBS
affected  ||| S:1470 E:1479 ||| VBN
by  ||| S:1479 E:1482 ||| IN
hypertension  ||| S:1482 E:1495 ||| NN
and  ||| S:1495 E:1499 ||| CC
diabetes  ||| S:1499 E:1508 ||| NN
compared  ||| S:1508 E:1517 ||| VBN
with  ||| S:1517 E:1522 ||| IN
heart  ||| S:1522 E:1528 ||| NN
disease  ||| S:1528 E:1536 ||| NN
or  ||| S:1536 E:1539 ||| CC
any  ||| S:1539 E:1543 ||| DT
cancer ||| S:1543 E:1549 ||| NN
.  ||| S:1549 E:1551 ||| .
Female  ||| S:1551 E:1558 ||| JJ
participants  ||| S:1558 E:1571 ||| NNS
had  ||| S:1571 E:1575 ||| VBD
a  ||| S:1575 E:1577 ||| DT
higher  ||| S:1577 E:1584 ||| JJR
prevalence  ||| S:1584 E:1595 ||| NN
of  ||| S:1595 E:1598 ||| IN
heart  ||| S:1598 E:1604 ||| NN
disease  ||| S:1604 E:1612 ||| NN
compared  ||| S:1612 E:1621 ||| VBN
with  ||| S:1621 E:1626 ||| IN
the  ||| S:1626 E:1630 ||| DT
Canadian  ||| S:1630 E:1639 ||| JJ
average ||| S:1639 E:1646 ||| NN
.  ||| S:1646 E:1648 ||| .
Primary  ||| S:1648 E:1656 ||| JJ
preventive  ||| S:1656 E:1667 ||| JJ
strategies  ||| S:1667 E:1678 ||| NNS
are  ||| S:1678 E:1682 ||| VBP
necessary  ||| S:1682 E:1692 ||| JJ
to  ||| S:1692 E:1695 ||| TO
mitigate  ||| S:1695 E:1704 ||| VB
the  ||| S:1704 E:1708 ||| DT
increasing  ||| S:1708 E:1719 ||| VBG
rates  ||| S:1719 E:1725 ||| NNS
of  ||| S:1725 E:1728 ||| IN
chronic  ||| S:1728 E:1736 ||| JJ
disease  ||| S:1736 E:1744 ||| NN
risk  ||| S:1744 E:1749 ||| NN
factors  ||| S:1749 E:1757 ||| NNS
in  ||| S:1757 E:1760 ||| IN
this  ||| S:1760 E:1765 ||| DT
population ||| S:1765 E:1775 ||| NN
.  ||| S:1775 E:1777 ||| .
Further  ||| S:1777 E:1785 ||| JJ
studies  ||| S:1785 E:1793 ||| NNS
with  ||| S:1793 E:1798 ||| IN
a  ||| S:1798 E:1800 ||| DT
larger  ||| S:1800 E:1807 ||| JJR
sample  ||| S:1807 E:1814 ||| NN
size  ||| S:1814 E:1819 ||| NN
and  ||| S:1819 E:1823 ||| CC
measured  ||| S:1823 E:1832 ||| VBN
chronic  ||| S:1832 E:1840 ||| JJ
disease  ||| S:1840 E:1848 ||| NN
are  ||| S:1848 E:1852 ||| VBP
necessary  ||| S:1852 E:1862 ||| JJ
to  ||| S:1862 E:1865 ||| TO
confirm  ||| S:1865 E:1873 ||| VB
the  ||| S:1873 E:1877 ||| DT
findings  ||| S:1877 E:1886 ||| NNS
obtained  ||| S:1886 E:1895 ||| VBN
in  ||| S:1895 E:1898 ||| IN
the  ||| S:1898 E:1902 ||| DT
present  ||| S:1902 E:1910 ||| JJ
study ||| S:1910 E:1915 ||| NN
.  ||| S:1915 E:1917 ||| .
